Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

Blood

Volumn 103, Issue 12, 2004, Pages 4396-4407

  Thomas, Deborah A ^a   Faderl, Stefan ^b   Cortes, Jorge ^b   O'Brien, Susan ^b   Giles, Francis J ^b   Kornblau, Steven M ^b   Garcia Manero, Guillermo ^b   Keating, Michael J ^b   Andreeff, Michael ^b   Jeha, Sima ^b   Beran, Miloslav ^b   Verstovsek, Srdan ^b   Pierce, Sherry ^b   Letvak, Laurie ^b   Salvado, August ^b   Champlin, Richard ^b   Talpaz, Moshe ^b   Kantarjian, Hagop ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; IMATINIB; METHOTREXATE; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLOOD CLOTTING DISORDER; BONE PAIN; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONSTIPATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; FATIGUE; FEMALE; FLUID RETENTION; FOLLOW UP; FRACTURE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART ARRHYTHMIA; HEART EJECTION FRACTION; HERPES ZOSTER; HUMAN; HUMAN CELL; HYPOFIBRINOGENEMIA; HYPONATREMIA; ILEUS; LEUKEMIA REMISSION; LIVER TOXICITY; MAINTENANCE THERAPY; MALE; MYALGIA; NAUSEA; NEPHROTOXICITY; OSTEOMYELITIS; OUTCOMES RESEARCH; PERIPHERAL NEUROPATHY; PHILADELPHIA 1 CHROMOSOME; PNEUMONIA; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; RASH; REFLUX ESOPHAGITIS; RELAPSE; SEPSIS; SINUSITIS; STEM CELL TRANSPLANTATION; STOMATITIS; SYNCOPE; TREATMENT FAILURE; UPPER RESPIRATORY TRACT INFECTION;

EID: 2942567555     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-08-2958     Document Type: Article

References (83)

1. Faderl S, Kantarjian HM, Talpaz M, Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood. 1998;91:3995-4019.
2. Schlieben S, Borkhardt A, Reinisch I, et al. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL): a prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM 90 and CoALL-05-92. Leukemia. 1996;10:957-963.
3. Gokbuget N, Hoelzer D, Arnold R, et al. Treatment of adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am. 2000;14:1307-1325.
4. Durrant IJ, Richards SM, Prentice HG, Goldstone AH. The Medical Research Council trials in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2000;14:1327-1352.
5. Thiebaut A, Vemant JP, Degos L, et al. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation: a follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am. 2000;14:1353-1366.
6. Larson RA. Recent clinical trials in acute lymphocytic leukemia by the Cancer and Leukemia Group B. Hematol Oncol Clin North Am. 2000;14:1367-1379.
7. Faderl S, Kantarjian HM, Thomas DA, et al. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma. 2000;36:263-273.
8. Garcia-Manero G, Kantarjian HM. The hyper-CVAD regimen in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2000;14:1381-1396.
9. Preti HA, O'Brien S, Giralt S, Beran M, Pierce S, Kantarjian HM. Philadelphia-chromosome-positive adult acute lymphocytic leukemia: characteristics, treatment results, and prognosis in 41 patients. Am J Med. 1994;97:60-65.
10. Radich JP. Philadelphia chromosome-positive acute lymphocytic leukemia. Hematol Oncol Clin North Am 2001;15:21-36.
11. Arico M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med. 2000;342:998-1006.
12. +) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. Blood. 1988;92:2730-2741.
13. Forman SJ, O'Donnell MR, Nademanee AP, et al. Bone marrow transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 1987;70:587-588.
14. Barrett AJ, Horowitz MM, Ash RC, et al. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 1992;79:3067-3070.
15. Chao NJ, Blume KG, Forman SJ, Snyder DS. Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1995;85:3353-3354.
16. Snyder DS, Nademanee AP, O'Donnell MR, et al. Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission. Leukemia. 1999;13:2053-2058.
17. Snyder DS. Allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2000;6:597-603.
18. Avivi I, Goldstone AH. Bone marrow transplant in Ph+ ALL patients. Bone Marrow Transplant. 2003;31:623-632.
19. Bartram CR, de Klein A, Hagemeijer A, et al. Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1983;306:277-280.
20. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myeloid leukaemia. Nature. 1985;315:550-554.
21. Gleissner B, Gokbuget N, Bartram CR, et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood. 2002;99:1536-1543.
22. Kantarjian HM, Talpaz M, Dhingra K, et al. Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia. Blood. 1991;78:2411-2418.
23. Secker-Walker LM, Craig JM, Hawkins JM, Hoffbrand AV. Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance. Leukemia. 1991;5:196-199.
24. Radich J, Gehly G, Lee A, et al. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood. 1997;89:2602-2609.
25. Daley GQ, Van Etten RA, Baltimore D, et al. Induction of chronic myelogenous leukaemia in mice by the P210 bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824-830.
26. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247:1079-1082.
27. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000;295:139-145.
28. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.
29. Fang G, Kim CN, Perkins CL, et al. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood. 2000;96:2246-2253.
30. Beran M, Cao X, Estrov Z, et al. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res. 1998;4:1661-1672.
31. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
32. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.
33. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928-1937.
34. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530-3539.
35. Kantarjian HM, Talpaz M, O'Brien S, et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res. 2002;8:2177-2187.
36. Kantarjian HM, O'Brien S, Cortes JE, et al. Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res. 2002;8:2167-2176.
37. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.
38. Kantarjian HM, Cortes JE, O'Brien S, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood. 2003;101:97-100.
39. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038-1042.
40. Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. 2002;100:1965-1971.
41. Wassmann B, Pfeifer H, Scheuring U, et al. Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Leukemia. 2002;16:2358-2365.
42. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-880.
43. Hofmann WK, Komor M, Wassmann B, et al. Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood. 2003;102;659-661.
44. Tipping AJ, Melo JV. Imatinib mesylate in combination with other chemotherapeutic drugs: in vitro studies. Semin Hematol. 2003;40(suppl 3):83-91.
45. Avramis IA, Laug WE, Sausville EA, Avramis VI. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines. Cancer Chemother Pharmacol. 2003;52:307-318.
46. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18:547-561.
47. Cortes J, O'Brien SM, Pierce S, et al. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood. 1995;86:2091-2097.
48. Kantarjian HM, Smith TL, O'Brien S, et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. Ann Intern Med. 1995;122:254-261.
49. Kantarjian HM, Talpaz M, Cortes J, et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; Gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res. 2003;9:160-166.
50. Kantarjian HM, Walters RS, Keating MJ, et al. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. J Clin Oncol 1990;8:994-1004.
51. Thomas DA, Cortes J, Giles FJ, et al. The modified hyper-CVAD regimen in newly diagnosed adult acute lymphoblastic leukemia (ALL) [abstract]. Blood 2001;98(suppl 1):590a. Abstract no. 2474.
52. Cox DR. Regression models and life tables. J R Stat Soc [B]. 1972;34:187-220.
53. Kaplan EL, Meier P. Non-parametric estimation form incomplete observations. J Am Stat Assoc. 1965;53:457-481.
54. Bloomfield CD, Secker-Walker LM, Goldman AI, et al. Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia. Cancer Genet Cytogenet. 1989;40:171-185.
55. Gotz G, Weh HJ, Walter TA, et al. Clinical and prognostic significance of the Philadelphia chromosome in adult patients with acute lymphoblastic leukemia. Ann Hematol. 1992;64:97-100.
56. Westbrook CA, Hooberman AL, Spino C, et al. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study. Blood. 1992;80:2983-2990.
57. Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995;85:2025-2037.
58. Group Francais de Cytogenetique Hematologique. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings outcome: a Collaborative Study of the Group Francais de Cytogenetique Hematologique [erratum in: Blood 1996;88:2818]. Blood. 1996;87:3135-3142.
59. Group Francais de Cytogenetique Hematologique. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings outcome: a Collaborative Study of the Group Francais de Cytogenetique Hematologique [erratum in: Blood 1996;88:2818]. Blood. 1996;87:3135-3142.
60. Chim CS, Kwong YL, Chu YC, et al. Improved treatment outcome in adult acute lymphoblastic leukemia using the intensive German protocol, a preliminary report. Hematol Oncol. 1997;15:19-26.
61. Secker-Walker LM, Prentice HG, Durrant J, et al. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA: MRC Adult Leukaemia Working Party. Br J Haematol. 1997;96:601-610.
62. Thomas X, Thiebaut A, Olteanu N, et al. Philadelphia chromosome postitive adult acute lymphoblastic leukemia: characteristics, prognostic factors and treatment outcome. Hematol Cell Ther. 1998;40:119-128.
63. Wetzler M, Dodge RK, Mrozek K, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: The cancer and leukemia Group B experience. Blood. 1999;93:3983-3993.
64. Ko BS, Tang JL, Tsai W, et al. Philadelphia chromosome-positive acute lymphoblastic leukemia in Taiwan. Ann Hematol. 2001;80:510-515.
65. Thomas X, Danaila C, Le QH, et al. Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: A single institution experience of 378 consecutive patients over a 21-year period. Leukemia. 2001;15:1811-1822.
66. Annino L, Vegna ML, Camera A, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood. 2002;99:863-871.
67. Dombret H, Gabert J, Boiron JM, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia-results of the prospective multicenter LALA-94 trial. Blood. 2002;100:2357-2366.
68. Stockschlader M, Hegewisch-Becker S, Kruger W, et al. Bone marrow transplantation for Philadelphia-chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant. 1995;16:663-667.
69. Sierra J, Radich J, Hansen JA, et al. Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 1997;90:1410-1414.
70. Goldstone AH, Prentice HG, Durrant IJ, et al. Allogeneic transplant (related or unrelated donor) is the preferred treatment for adult Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL): Results from the International ALLTrial (MRC UKALLXII/ECOG E2993) [abstract]. Blood. 2001;98:856a.
71. Cornelissen JJ, Carston M, Kollman C, et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood. 2001;97:1572-1577.
72. Lee S, Kim DW, Cho B, et al. Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: The potential of real-time quantitative reverse-transcription polymerase chain reaction. Br J Haematol. 2003;120:145-153.
73. Gleissner B, Rieder H, Thiel E, et al. Prospective BCR-ABL analysis by polymerase chain reaction (RT-PCR) in adult acute B-lineage lymphoblastic leukemia: Reliability of RT-nested-PCR and comparison to cytogenetic data. Leukemia. 2001;15:1834-1840.
74. Radich JP. Molecular measurement of minimal residual disease in Philadelphia-positive acute lymphoblastic leukaemia. Best Pract Res Clin Haematol. 2002;15:91-103.
75. Stirewalt DL, Guthrie KA, Beppu L, et al. Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation. Biol Blood Marrow Transplant. 2003;9:206-212.
76. Scheuring UJ, Pfeifer H, Wassmann B, et al. Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571). Blood. 2003;101:85-90.
77. Mitterbauer G, Nemeth P, Wacha S, et al. Quantification of minimal residual disease in patients with BCR-ABL-positive acute lymphoblastic leukaemia using quantitative competitive polymerase chain reaction. Br J Haematol. 1999;106:634-643.
78. Hofmann WK, de Vos S, Elashoff D, et al. Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet. 2002;359:481-486.
79. Wolff NC, Richardson JA, Egorin M, Ilaria RL Jr. The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. Blood. 2003;101:5010-5013.
80. Takayama N, Sato N, O'Brien SG, et al. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol. 2002;119:106-108.
81. Thomas DA, Cortes J, Giles FJ, et al. Combination of hyper-CVAD with imatinib mesylate (STI571) for Philadelphia (Ph)-positive adult acute lymphoblastic leukemia (ALL) or chronic myelogenous leukemia in lymphoid blast phase (CML-LBP). Blood. 2001;98:803a.
82. Thomas DA, Cortes J, Garcia-Manero G, et al. Minimal residual disease (MRD) after hyper-CVAD and imatinib mesylate (STI571) for Philadelphia (Ph) positive adult acute lymphoblastic leukemia (ALL). Blood. 2002;100:764a.
83. Thomas DA, Garcia-Manero G, Cortes J, et al. Results of intensive chemotherapy with hyper-CVAD and imatinib mesylate in Philadelphia (Ph) positive acute lymphocytic leukemia (ALL). Proc Am Soc Clin Oncol. 2003;22:588.